ADRA2A and COVID-19: ADRA2 agonists are believed to reduce mortality related to hyperinflammation and acute respiratory failure in COVID-19 patients, as well as to have immunomodulatory effects by maintaining endothelial junction integrity and reducing immune cell activity even when an inflammatory stimulus is present (Hamilton et al., 2022).